Latest Tumor necrosis factors Stories
A novel anti-inflammatory approach produced a significant reduction in stroke size and neural deficit in an animal model. The animal study follows publication by the INR (CNS Drugs, 2011.
Researchers at Boston University School of Medicine (BUSM) have identified a gene that plays a key role in regulating inflammatory response and homeostasis.
Glioblastoma, a lethal brain cancer, is one of the most resistant to available therapies and patients typically live approximately 15 months.
Researchers of VIB and UGent have discovered a new approach to preventing septic shock, an often fatal extreme inflammatory reaction of the body.
Sepsis, a form of systemic inflammation, is the leading cause of death in critically ill patients.
Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of skin cancer, indicates a systematic review of published research in the Annals of the Rheumatic Diseases.
A powerful pro-inflammatory protein, tumor necrosis factor (TNF), can suppress aspects of inflammation.
MALVERN, Pa., May 24, 2011 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced that is has closed a $6 million investment with new investor Nextech Invest Ltd., a Zurich, Switzerland, based oncology focused venture capital fund.
Reporting in Nature, scientists from Thomas Jefferson University have determined that a single protein called FADD controls multiple cell death pathways, a discovery that could lead to better, more targeted autoimmune disease and cancer drugs.
MALVERN, Pa., Jan. 5, 2011 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced that is has closed the $23 million second tranche of a Series C financing completed in October 2010.
- The abrogation of a law by a higher authority; annulment.